MoonLake Immunotherapeutics Stock (MLTX)

Track MoonLake Immunotherapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.

$15.60

▼ -39.07 (-71.52%) past year

Closed · Updated Aug 26, 7:59 PM

Market Cap

$1.31B

P/E Ratio

—

1Y Return

-71.52%

EPS (TTM)

-$3.84

Read the latest TheStreet Pro articles mentioning MoonLake Immunotherapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.

Articles

3 articles

trade-ideas I'm Over the Moon About This Promising Biotech
Bret JensenAug 17, 2025
MLTX MRK
trade-ideas Two Biotechs That Could Get an M&A Boost
Bret JensenJun 4, 2025
MLTX SNY MRK
trade-ideas I'm Eyeing 2 Promising Biotech Plays as Oversold Market Gets Under My Skin
Bret JensenOct 25, 2024
MLTX NTLA

Daily Diary Mentions

1 mention

Sep 30 · 6:30 PMConcentration Can Kill
* Another lesson learned... This is a story of a well-regarded multi-billion-dollar healthcare hedge fund, BVF (Biotechnology Value Fund), founded in 1993, which had a near 35% holding (19.7 million shares) in MoonLake I…
MLTX
Read in context ›